Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL28540970 | 0.94 | MAPT (0.34) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL29804885 | 0.94 | MAPT (0.37) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL16341187 | 0.94 | MAPT (0.37) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL3662203 | 0.94 | MAPT (0.37) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL8924 | 0.94 | MAPT (0.37) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL7679307 | 0.91 | MAPT (0.36) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL3201327 | 0.91 | MAPT (0.36) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| Methane SCHEMBL17891768 | 0.91 | MAPT (0.36) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL7679297 | 0.91 | MAPT (0.36) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL21822066 | 0.91 | MAPT (0.36) | MAPTKDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919334-B2 | Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine | WYETH (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040127493-A1 | Antidepressant azaheterocyclylmethyl derivatives of 4,5-dihydroimidazo[1,4,5-de ][1,4]benzoxazine | WYETH | 2004-07-01 | — | — | US | disclosed |
| WO-2004024736-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 4,5-DIHYDROIMIDAZO[1,4,5-DE]BENZOXAZINE | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127493-A1 | Antidepressant azaheterocyclylmethyl derivatives of 4,5-dihydroimidazo[1,4,5-de ][1,4]benzoxazine | CYP19A1, HTR5A, HSD17B11 | MAPT 3132/4885KDM4E 1405/4885MEN1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.